Understand KRAS and the Quest for Anti-Cancer Drugs

The KRAS oncogene is mutated in approximately ~30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling p...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Chang Woo, Jeong, Mi Suk, Jang, Se Bok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068306/
https://www.ncbi.nlm.nih.gov/pubmed/33917906
http://dx.doi.org/10.3390/cells10040842
_version_ 1783683005202563072
author Han, Chang Woo
Jeong, Mi Suk
Jang, Se Bok
author_facet Han, Chang Woo
Jeong, Mi Suk
Jang, Se Bok
author_sort Han, Chang Woo
collection PubMed
description The KRAS oncogene is mutated in approximately ~30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development.
format Online
Article
Text
id pubmed-8068306
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80683062021-04-25 Understand KRAS and the Quest for Anti-Cancer Drugs Han, Chang Woo Jeong, Mi Suk Jang, Se Bok Cells Review The KRAS oncogene is mutated in approximately ~30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development. MDPI 2021-04-08 /pmc/articles/PMC8068306/ /pubmed/33917906 http://dx.doi.org/10.3390/cells10040842 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Han, Chang Woo
Jeong, Mi Suk
Jang, Se Bok
Understand KRAS and the Quest for Anti-Cancer Drugs
title Understand KRAS and the Quest for Anti-Cancer Drugs
title_full Understand KRAS and the Quest for Anti-Cancer Drugs
title_fullStr Understand KRAS and the Quest for Anti-Cancer Drugs
title_full_unstemmed Understand KRAS and the Quest for Anti-Cancer Drugs
title_short Understand KRAS and the Quest for Anti-Cancer Drugs
title_sort understand kras and the quest for anti-cancer drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068306/
https://www.ncbi.nlm.nih.gov/pubmed/33917906
http://dx.doi.org/10.3390/cells10040842
work_keys_str_mv AT hanchangwoo understandkrasandthequestforanticancerdrugs
AT jeongmisuk understandkrasandthequestforanticancerdrugs
AT jangsebok understandkrasandthequestforanticancerdrugs

Ejemplares similares